AbbVie Price to Free Cash Flow Ratio 2010-2023 | ABBV
Historical price to free cash flow ratio values for AbbVie (ABBV) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| AbbVie Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-04-24 |
167.80 |
|
13.49 |
| 2023-12-31 |
152.05 |
$12.44 |
12.22 |
| 2023-09-30 |
144.81 |
$13.94 |
10.39 |
| 2023-06-30 |
129.45 |
$13.96 |
9.27 |
| 2023-03-31 |
151.75 |
$13.23 |
11.47 |
| 2022-12-31 |
152.40 |
$13.64 |
11.17 |
| 2022-09-30 |
125.32 |
$12.34 |
10.15 |
| 2022-06-30 |
141.69 |
$12.50 |
11.33 |
| 2022-03-31 |
148.65 |
$12.40 |
11.99 |
| 2021-12-31 |
122.86 |
$12.37 |
9.93 |
| 2021-09-30 |
96.73 |
$12.77 |
7.57 |
| 2021-06-30 |
99.90 |
$11.31 |
8.83 |
| 2021-03-31 |
94.81 |
$10.19 |
9.30 |
| 2020-12-31 |
92.80 |
$10.04 |
9.25 |
| 2020-09-30 |
74.83 |
$8.98 |
8.33 |
| 2020-06-30 |
82.89 |
$9.07 |
9.14 |
| 2020-03-31 |
63.41 |
$9.13 |
6.94 |
| 2019-12-31 |
72.72 |
$8.61 |
8.45 |
| 2019-09-30 |
61.30 |
$8.50 |
7.21 |
| 2019-06-30 |
57.99 |
$8.46 |
6.86 |
| 2019-03-31 |
63.42 |
$8.65 |
7.33 |
| 2018-12-31 |
71.65 |
$8.27 |
8.66 |
| 2018-09-30 |
72.73 |
$7.78 |
9.35 |
| 2018-06-30 |
70.54 |
$6.81 |
10.35 |
| 2018-03-31 |
71.32 |
$6.21 |
11.48 |
| 2017-12-31 |
72.36 |
$5.88 |
12.30 |
| 2017-09-30 |
66.02 |
$5.28 |
12.51 |
| 2017-06-30 |
53.40 |
$4.13 |
12.94 |
| 2017-03-31 |
47.51 |
$1.00 |
47.63 |
| 2016-12-31 |
45.19 |
$0.91 |
49.80 |
| 2016-09-30 |
45.09 |
$1.20 |
37.64 |
| 2016-06-30 |
43.88 |
$1.43 |
30.70 |
| 2015-12-31 |
41.12 |
$4.28 |
9.61 |
| 2015-09-30 |
37.42 |
$3.71 |
10.10 |
| 2015-06-30 |
45.87 |
$3.76 |
12.21 |
| 2015-03-31 |
39.63 |
$3.72 |
10.67 |
| 2014-12-31 |
43.96 |
$3.80 |
11.57 |
| 2016-03-31 |
40.09 |
$3.51 |
11.41 |
| 2014-09-30 |
38.51 |
$2.96 |
13.00 |
| 2014-06-30 |
37.35 |
$3.01 |
12.41 |
| 2014-03-31 |
33.71 |
$3.22 |
10.47 |
| 2013-12-31 |
34.35 |
$3.60 |
9.54 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$297.115B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
